A Selection of company profiles is available below

Cleantech AER Bio 2Eisergy 4Enverian 5Gaelectric Energy Storage 7Ikon Semiconductor 8

Software & Telecoms Betapond 10Brite:bill 12Cubic Telecom 14CurrencyFair 16ePub Direct 18Eventovate 20Global Business Register 22Lighthouse BCS 24OmniMotion 26 Phorest 28ServiceFrame 30UniVirtua 32

Lifesciences Crescent Diagnostics 34Inflection Biosciences 36Metabolomic Diagnostics 38Radisens Diagnostics 40Sigmoid Pharma 42Solvotrin Therapeutics 44Surgacoll 46TriMod Therapeutics 48

AER Bio NIBRT, Fosters Avenue, Mount Merrion, Dublin www.aer.ie

Company Overview AER develops enzymes which enable a new low-cost, scalable process for extracting useful products from algae. Algae are aquatic plants such as phytoplankton and seaweed. We target 2 separate end-user markets; nutritional products and biofuels. We partner with leading food and energy companies to bring the technology to market.

Algae is used commercially to manufacture a range of natural food ingredient products including Omega-3 and Omega-6 oils, carotenoids and alginates. Algae is also being developed as a highly sustainable feedstock for 2nd generation biofuel. Food and energy majors (e.g. BASF, Royal DSM, L’Oreal, Exxon Mobil, GDF Suez, Dupont, Cargill) and well-capitalised startups (e.g. Solazyme, Sapphire Energy) have begun to roll out commercial-scale algae production facilities to address these markets globally.

Market Opportunity The traditional method for extracting products from microalgae uses hexane as a chemical solvent. This approach is too energy-intensive and expensive for biofuel production. US Dept of Energy analysis indicates that a further reduction in extraction costs of at least 50% is required to compete with conventional fuel sources. Hexane is also toxic and carcinogenic. Organically sourced nutritional products command a significant market premium. Some manufacturers use supercritical fluid extraction to address this market, but this approach is more expensive still.

Revenue Model Product Sales, Licensing

Product AER’s proprietary enzyme products rapidly digest the cell walls of algae, releasing the valuable products inside. The AER-enabled process is efficient, scalable and 100% natural. Using the technology, customers can reduce production costs and open new markets.

AER’s enzyme products allow customers to replace a dirty, inefficient chemical extraction process with a low-cost, scalable, clean biochemical alternative.

Management Team CEO Donal Mac Nioclais is former Commercial Manager with renewable energy technology developer, Aquamarine Power. Previously, Donal held consulting and sales positions with McKinsey and Accenture. MBA with distinction from INSEAD.

CSO Dr. Henrik Møllgaard has 30 years of senior industrial experience in enzyme development and microbiology R&D, gained with industry leaders Novozymes and ChristianHansen. PhD in biochemistry from Copenhagen University.

2

Head of Business Development Lambert van Orsouw has 25 years in enzyme sales with industry leaders Genencor, AB Enzymes and Gist Brocades (now DSM). Scientific Advisor Professor Maria Tuohy is the Head of the Molecular Glycobiotechnology Group at NUI Galway.

Director Declan Ryan is Chairman of Irelandia Investments, a pioneering VC which has led the global development of low-cost aviation through its investments in Ryanair (Europe), Tiger Airways (Asia), Allegiant Air (USA) and Viva Aerobus (Lat-Am).

Director Dr. John Teeling is former Chairman of Cooley Distillery, the major Irish whiskey producer acquired in 2011 by Beam Inc. for $95m.

Director John Travers is Managing Director of DCC New Energy, the renewable energy arm of the $1.5bn ISEQ-listed company, DCC Group plc. John previously held positions at Shell and McKinsey. MBA from Harvard.

Target Markets Food Sector, Biofuels Producers

Funding Requirement €2,000,000

3

Eisergy 32 Morehampton Road, Dublin 4

Company Overview Eisergy Limited has been formed to realize profitable opportunities in the area of modules for offline (ACDC) power conversion. The founder has worked in the power conversion space for some time, and this represents a “second launch.

Market Opportunity Power conversion products are currently almost always crafted from basic components such as resistors, capacitor, switches etc, along with magnetics and control integrated circuits. The technical and economic factors have changed in recent years to allow cost-competitive design of modules for the key power conversion.

Three “demonstrator products”, also associated with wide market coverage, are planned initially – one for power factor correction and two types of isolation stage. Eisergy is also promoting commercialisation of magnetic materials technology as developed at Tyndall National Institute, Cork, Ireland to offer additional performance differentiation in these products.

Product Eisergy is coming up with efficient, cost-effective solutions for the principal “building block” stages as used in volume power conversion products.

Revenue Model The overall power conversion market space – taking in “traditional” power conversion, lighting and similar areas – represents a market worth ~$20bn annually. The “conventional” approach is limited by talent constraints with manufacturers and very few suppliers to the industry are able to take the “integrated view” encompassing control, magnetics and other key elements to deriving cost-effective competitive advantage.

Management Team The Chief Executive is George Young. After earlier career periods in electronics design and in venture capital and corporate finance areas, he established Commergy Limited in 1998, sold in 2008. The breadth of experience, as well as knowing many key participants in the power conversion sector, positions Eisergy to lead in this area and attract a very capable team as products are demonstrated.

Milestones Initial product designs specified and simulated

Target Markets Electronic OEMs

Funding Requirement €2,000,000

4

Enverian Alexandra House, The Sweepstakes, Ballsbridge, Dublin 4 www.enverian.com

Company Overview Enverian was established in 2011 to provide innovative, complex and flexible business solutions to the energy sector. The company is led by a Senior Management team with extensive experience of delivering key strategic initiatives in Renewable Energy, High-Tech, Software, Biotechnology, Financial, Utilities, and IT environments.

Market Opportunity Enverian provides the answer to many of the biggest management challenges facing renewable energy development companies. Enverian’s innovative business solution brings an international standards-based approach to project tracking, ranking and valuing.

Enverian’s Renewable Portfolio Manager is a business solution that assists energy companies to manage a portfolio of energy development opportunities. Its unique selling points are:

• Tracks, Ranks and Values development opportunities from the earliest stage

• Provides company-wide view of portfolio information to all stake-holders

• Empowers Project Managers to run indicative financials and measure progress in a consistent way

• Keeps financial values updated with changes in underlying data such as power prices

• Enhances Board level investment decisions

• Generates configurable portfolio reports with key details and status updates

Revenue Model Enverian’s revenue model is based on software licensing, support and maintenance contracts and also consulting revenue associated with implementations or specialist knowledge based services (e.g. financial model development or process tracking schedule development).

Management Team Colin Rogan has over 30 years’ experience working in high technology companies in Ireland and the US. During his career Colin has held positions as CIO at Airtricity, CIO at IONA Technologies, and IT Director at Oracle Ireland. Colin was recently the President of the AIM Ireland.

Alan Carey has a track record of working with large multinationals on key strategic programmes including working with clients to raise significant equity investment. By holding a senior strategist position in Airtricity and Scottish & Southern Energy Plc, he has been instrumental in transforming how these companies operate and grow.

Bernard Carroll has over 18 years’ experience in software business solutions consulting.

Milestones May 2011 First Client – Mainstream Renewable Power

Jun 2011 Started development of the product

Dec 2011 Closed First Round Funding of €1,000,000

5

April 2012 Secured Second Irish Client – Reforce Energy Ltd

May 2012 Won VC-Backed Startup of the Year (Vodafone sponsored competition)

Jun 2012 Nominated for Global Cleantech Cluster Association 2012 Later Stage Award

July 2012 First US based client – BrightSource (largest Solar Company in the US)

Target Markets Utilities – established energy companies that will have a division responsible for Renewable Energy Generation.

Development Companies – these are well funded Energy Asset Development companies (e.g. Wind Farm developers). They are characterized by developing a portfolio of assets, most likely on an international footing and their strategy is normally to develop an opportunity and sell it before it is built.

Small Developers – these organisations are small in size and will be developing only a small number of assets in a given timeframe (maybe 2-3 per year). They will be cash constrained and focused on disposing of development assets as soon as possible.

Funding Requirement

€4,000,000

6

Gaelectric Energy Storage Portview House, Dublin 4 www.gaelectric.ie

Company Overview As the foremost grid-scale storage integration company in Europe, Gaelectric is developing a grid storage platform comprising products and services that would be licensable to a global market for utility scale storage facilities such as CAES, Pumped Storage and Battery Storage. The global market for grid-scale storage by 2017 is estimated to be 50GW (Lux Research 2012).

Market Opportunity Europe cannot meet nor exceed its renewables targets without the deployment of storage. The deployment and operation of storage for renewables management requires sophisticated tools and systems which do not currently exist.

Gaelectric is developing a platform which will enable the design, development, optimization and operation of grid storage. Platform products will enable system operators, utilities, trading houses and renewables’ owners to integrate storage understanding its application into the grid and existing asset bases.

Management Team Team of 7, consisting of project financiers, geologists, physicists, project and planning managers and commercial experts. The senior team has more than 10 years of sectoral experience.

Milestones Partnerships with world-leading CAES, flywheel and battery storage providers near completion.

Scoping of demonstration projects within one of the world’s highest wind regimes across CAES, flywheel and battery underway

Target Markets Electricity Grid Operators, Storage Developers

Funding Requirement €2,000,000

7

Ikon Semiconductor NCI Business Campus, Dublin 1 www.ikonsemi.com

Company Overview Ikon Semiconductor is a fabless semiconductor company which is developing highly innovative, silicon, LED Driver solutions for the LED lighting market. By applying proprietary digital control techniques, where traditionally analog control techniques have been used, Ikon Semiconductor is developing a solution which offers significant benefits to its customers. It results in a simpler design as well as reducing the size and cost of the overall solution.

The company currently has samples of its first product and will be sampling to a number of customers in the Oct 2012 timeframe.

Market Opportunity Driven by increasing concerns over energy consumption and the environmental impact of greenhouse gases, legislation (e.g. the EU Ecodesign Directive - 2005/32/EC) is being introduced worldwide to phase-out the inefficient incandescent light bulb, and to replace it with low-energy alternatives. LED (Light Emitting Diode) technology is the fastest growing, low-energy, lighting technology. Ikon’s chips reside inside the LED “bulb”, and perform the function of converting the mains AC voltage into the precise DC current required to drive LED’s.

Ikon’s first product will target the residential and commercial bulb replacement market, where volumes of LED replacement lamps are predicted to grow at a CAGR > 100% from 80 million in 2011 to 430 million in 2013.

Revenue Model Ikon Semiconductor operates a “fabless semiconductor” business model. The company will sell their products through both distributors and a direct salesforce to LED lighting manufacturers. Chip manufacturing is outsourced to a major wafer foundry. The company is currently pre-revenue but is projecting revenues of >€5M by 2014.

Management Team Conor McAuliffe, CEO

• 24 years in the Semiconductor Industry.

• 7 years with US multinational Analog Devices, 1987 – 1994.

• 9 years with Irish Semiconductor company Parthus Technologies, 1994 –

2002.

• Co-founder of Silansys Technologies, 2002 – 2005. Silansys was successfully

sold to UK fabless semiconductor company Frontier Silicon in 2005 for €6M.

• 3 years at Frontier Silicon, 2005 – 2008.

Paul Grogan, CTO

• 14 years in the Semiconductor Industry

• 3 years with US multinational Analog Devices, 1995 – 1999.

• 4 years with Irish Semiconductor company Parthus Technologies, 1999 – 2003

8

• 2 years with Silansys Technologies, 2003 – 2005

• 4 years at Frontier Silicon, 2005 – 2009

Milestones 2009: Company founded by Conor McAuliffe and Paul Grogan.

2010: Raised a seed round of €400K.

2011: Filed first patent on our proprietary digital control technology.

2011: Raised follow on seed funding of €800K

2012: First samples available.

2012: Closed additional funding of €400K.

2012: Filed 2nd patent.

Target Markets 1. The first will be manufacturers of LED lighting products for the general illumination market who internally develop their own LED driver electronics.

2. The second category of customer will be manufacturers of LED driver modules for the LED lighting industry. These companies do not develop complete lighting solutions but develop the LED driver subsystem which they in turn sell to manufacturers of LED lighting products.

Funding Requirement

€3,000,000

9

Betapond 1 Bedford Avenue, London, WC1B 3AU www.betapond.com

Company Overview Betapond is the leading Facebook marketing technology development company in Europe.

Betapond is venture backed and currently employs 35. We specialize in working with global brands on implementing their Facebook technology strategy. Our approach is 100% based on driving meaningfull actionable data from Facebook.

Market Opportunity

The market for Facebook technology is quickly maturing as global brands go "beyond the like" in determining Facebook ROI and move from short term campaigns to long term solutions. Betapond is at the cutting edge of this technology transformation.

Revenue Model Enterprise technology solutions sales and software licensing

Management Team Declan Kennedy - CEO & Co Founder

Experience software entrepreneur. Based in London. Third startup in 5 years. Former investment banker .

Conor Ryan - COO & Co Founder.

Seasoned web product and software exec for past 15 years across a wide breath of industries and software verticals

Milestones Company Founded - November 2009

Love UK Top 50 (Facebook Checkins API) – October 2010

Opened London Office – January 2011

Facebook Preferred Developer - April 2011

€250,000 R&D Funding – June 2011

€1,115,000 - Seed Funding - December 2011

M&S Shwopping (March 2012) & Unilever Waterworks (Q3 2012)

Customers   Global Tier 1 Brands

10

Target Markets FMCG, Entertainment, Financial, Media, Retail

Funding Requirement

€2,000,000

11

Brite:bill Mayor Street, IFSC, Dublin 1 www.britebill.com

Company Overview Brite:Bill provides Communications Service Providers (CSPs) with a set of Billing Communications Products that creates a positive billing interaction with customers, pre-empting questions, tackling issues and highlighting appropriate new services.

Brite:Bill was founded by a group of individuals with a desire to improve the way companies spoke to their customers, and help individuals gain better control and understanding over their important home affairs. Trading since 2010, the company has grown to 30 people and now has offices in Dublin, London, Shanghai and San Francisco.

Revenue Model Our revenue model is selling perpetual software licenses with annual maintenance and hosting. We also offer Implementation, Creative and Advisory Services based on our solutions. We also offer SaaS models if preferred.

Management Team CEO – Alan Coleman ex Sales Director at Accenture, ex Macalla and Morgan Stanley

CTO – Jim Hannon ex Chief Architect at RTE, ex Macalla and Polar Lake

COO and CFO – Liam Davis ex CFO Norkom. Sold to BAE in 2011 for €200m+

Chairman – Cecil Hayes ex COO Norkom. Sold to BAE in 2011 for €200m+

Milestones Company Founded

Raised to date €3m

Clients now in both Ireland and in Europe

Customers   Eircom, Bank of Ireland, Vodafone, UPC, Tele2

12

Target Markets Telco and Utilities across Europe and North America

Funding Requirement

€2,000,000

13

Cubic Telecom Limited Unit 6 Oak Court, Oak Road, Western Business Park, Dublin 12 www.cubictelecom.com

Company Overview Cubic is a privately-owned Irish company headquartered in Dublin, Ireland. Cubic launched its unique platform in 2010 to meet the global demand from businesses and individuals for transparent and low-cost borderless data connectivity on mobile devices (tablets, notebooks and smartphones). Cubic has successfully developed the ability to provide high-quality, high-speed and low-cost pre-paid mobile access services (data, voice, SMS) on any connected device globally across multiple technologies including 3G/HSPA+, CDMA, Wi-Fi and LTE. Cubic has integrated its platform into the core of Tier 1 mobile networks, including Vodafone (3G/HSPA+), Sprint (CDMA), and Wi-Fi operators (iPass) to globally deploy Cubics multi-access technologies on any single device. Cubic has designed and built a global platform in-house supporting sophisticated e-Commerce, billing, self-care functions and customized white label solutions, which allow any OEM/Partner to become a branded mobile access provider quickly.

Market Opportunity The idea underpinning Cubic Telecom is to break the boundaries that are (and will be for a long time) a fundamental part of the mobile connectivity industry, by enabling high-quality, convenient and always-on global mobile connectivity at local prices. Cubic will complement the rapidly growing mobile connectivity industry (unit shipments for mobile connected devices is expected to reach 1.1 billion worldwide in 2012 and 1.84 billion units by 2016), prioritise effective mobile data and deliver a seamless experience to its partners and end-users. The key benefits of the Cubic technology is that it provides a convenient, transparent, low cost global mobile connectivity solution.

Revenue Model Cubic derives its revenue from the connectivity usage spend of end users. Cubic partners with worlds leading tablet / notebook manufacturers (“OEMs”), to embed Cubic’s technology at the manufacturing stage. Cubic’s technology and core network will enable these OEMs to offer affordable on-demand pre-paid data bundles to their customers in different regions of the world. Cubic also provides global solutions to telecom companies (fixed line, MNOs and MVNOs) and enterprises, enabling them to deliver customized global communications services under their own brand to their customers worldwide.

Management Team Barry Napier (Executive Chairman) - Experienced entrepreneur with 18 years in the telecom industry

Gerry McQuaid (Commercial Director) - Successful career in sales, marketing and management in IT and Telecom industries. Former main Board Director of Telefonica O2 Ireland

Pat Phelan (Product & Innovation) - 10 years in the Telecoms industry with extensive experience in the US/Europe

Kieran Sexton (Sales Director) - Involved in the Telecom, specifically mobile, industry for 20 years

Patrick Trane (CTO) - Vice President of Trusted Logic, CEO and co-founder Bantry Technologies

14

Milestones 2009: Global roaming agreement signed with Vodafone; MNO license awarded

2010: Launched Cubic platform; Enterprise Ireland investment confirmed; winners of Tech Crunch Europe Awards 2010

2011: Wholesale agreement signed with Vodafone UK; deployed multi-IMSI and Wi-Fi; integrated over 600,000 retail top up locations globally

2012: Qualcomm strategic partnership; agreements with Sprint, Everything Everywhere, iPass, Vodafone Aus, Boingo, China Unicom, PCCW and multiple OEMs under NDA; established Cubic USA

Customers Cubic will partner with leading OEMs, telcos and enterprises to provide end users with connectivity solutions:

HP (Global)

Google (US/Europe)

Lenovo (Global)

Woolworths (AUS)

easyJet (UK)

Target Markets Cubic is targeting the global mobile connectivity market. By partnering with Tier 1 network operators (Vodafone, Sprint, China Unicom), leading OEMs, telecom companies and enterprises, Cubic will provide end users with transparent and low-cost borderless data connectivity on mobile devices.

Funding Requirement €12,000,000

15

CurrencyFair 26 Pembroke Street Upper, Dublin 2 www.currencyfair.com

Company Overview CurrencyFair allows its customers to use a live, online, and regulated order-driven peer-to-peer marketplace to exchange and transfer GBP to EUR, EUR to GBP, or any other exchange between 17 supported currencies (more being added regularly). This saves the average customer 2.5% on the foreign exchange rate plus cuts the typical bank transfer fee from €25 to €3.

Since launching in 2010, CurrencyFair has facilitated the exchange of over €210 million (as of September 2012), and is currently seeing volumes averaging €1 million / day.

CurrencyFair was set up in 2009 by a team of four founders, led by Managing Director Brett Meyers. Three of the team had previously worked in banking and finance, and were also expats, so had direct experience with the pain and expense of sending money internationally.

Market Opportunity CurrencyFair aims to solve the pain experienced by anyone that has a need to send money abroad. This includes expats, foreign investors, people that own homes overseas, international students, and SMEs. Even though foreign exchange is the world’s biggest and most liquid financial market, banks will still charge around 3% commission, built into the exchange rate they quote, as well as €25-30 fixed ‘international transfer’ fee.

The savings with CurrencyFair are dramatic, as the exchange rates achieved are usually within 0-0.5% of the interbank rate, and the transfer fee is only €3.

Revenue Model CurrencyFair charges a 0.15% commission on matching customer trades. In addition, CurrencyFair supplies liquidity on the market in the event that p2p liquidity is insufficient to meet demand, and charges around 0.5% on this liquidity. Finally, CurrencyFair earns interest on client balances which long term will contribute another 0.05% to 0.1% of the volume exchanged.

Management Team Brett Meyers (CEO) - Over 15 years technology and banking experience.

Jonathan Potter (CFO) - Over 15 years banking experience.

Sean Barrett (Compliance and Risk) - Over 15 years banking experience. Senior Treasury Forex trader for Zurich Bank.

David Christian (CTO) - Over 15 years programming experience.

Milestones 2009 April - Company Founded

2010 May - Launched Online

2010 Dec - First €10 million exchanged

2011 Sep - First €50 million exchanged

2012 Feb - First €100 million exchanged

16

2012 Jun - First €150 million exchanged

2012 Jul - First monthly profit

2012 Sep - First €200 million exchanged

2012 Nov – First €250 million exchanged (projected)

Customers Retail product so no key reference customers. Over 5,000 customers have exchanged to date, from over 40 countries. Key markets are expats (working and retired) and SMEs across UK, Europe, Australia, Poland.

Target Markets Product is a retail product targetted at expats, international student, foreign property owners. SMEs currently make up 25% of volume. Primarily developed nation bank transfers at this stage rather than developing world remittance markets.

Funding Requirement €1,500,000

17

ePub Direct NSC Mahon, Mahon, Cork www.epubdirect.com

Company Overview ePubDirect provides digital distribution and management services to publishers and distributors. The company developed a custom built eBook distribution platform where publishers can upload their titles to a secure online account. The titles are then distributed to over 150 retail outlets including Amazon, Apple, Waterstones, Easons, Barnes & Noble, Sony Store and many more. The company also distributes to over 25,000 libraries. All distribution, administration and billing issues are dealt with by ePubDirect. Essentially the company provides a complete outsourced eBook management service.

Market Opportunity The digital book revolution is evolving rapidly. eBook sales worldwide have risen exponentially in the past 3 years, now outstripping print sales on occasions. After extensive market research and consultation with existing clients, it became apparent that publishers did not have the technical or financial resources in-house to successfully engage with this rapid growth. ePub's custom built distribution platform meets that need. ePub's competitive advantages include extensive market reach to retail outlets for customers, cost and time savings and an 'all in one' offering for customers for book conversion, distribution and administration services as well as consulting and marketing services.

Revenue Model The product is operated on a SaaS basis. Publishers are charged a monthly fee providing the company with regular, recurring income.

The company also retains a percentage of the retail price of each title.

Customers also require some pre-distribution work such as converting their existing titles to eBooks, creating book apps and general consultancy. This significantly boosts the value of each customer. Additional revenue is earned from marketing services and selling various levels of analytics/reporting packages to customers.

Management Team Gareth Cuddy, CEO and founder of ePub Direct. Gareth previously held Sales & Marketing roles with international companies

Aiven Hyland, COO. Over twelve years of international project management and operations management experience at senior management level. Ex global director at Capgemini, Smurfits and SouthWestern.

Patrick Crowley, Digital Marketing Manager. 7 years experience in publishing industry. Ex Mercier Press.

Mark Watkins, Head of IT. Over 9 years experience heading up eCommerce and IT departments

18

Milestones 2009: eBook store DirecteBooks launched

2010: Launched ePubDirect distribution platform

2011: Secured venture capital funding from NCB

2011: Exhibited and ran speaking events at key international book fairs which provided a major boost in client sign on.

2011: Won a number of awards including Cork Chamber emerging enterprise of the Year , IT@Cork High potential startup of the year , UlsterBank start-up of the year Munster and national finalist and overall winner of the Genesis enterprise program

2012: Strengthened the company's management team

2012: The company will launch Ireland’s first eBook conference in Dublin in September

Customers Key wins include Gill & Macmillan – Ireland’s largest publisher and distributor, TBS UK – Largest book distributor UK, Media 24 – South Africa, Bonnier – global publishing group and Primento - France.

Target Markets ePubDirect's core target markets are medium to large publishers, both Trade and Academic and traditional distribution companies that require a digital offering. Key target countries are the UK and the US.

Funding Requirement €5,000,000

19

Eventovate NCI R&D Centre, IFSC, Dublin 1 www.eventovate.com

Company Overview Eventovate develops and sells online software that is revolutionising the way venues and their customers (engaged couples) plan and manage weddings. The market is highly fragmented, ripe for innovation and we have successfully proven a scalable ability to generate €100 revenue per wedding (5 million weddings in UK & Europe per year) with the potential to increase this 50x. The company has a client list of top-tier international customers (e.g. K-Club & Old Course St Andrews).

Market Opportunity Most people only plan their wedding once and 95% of them have no experience in managing an event with 100+ guests and significant complexity. The venue is the first supplier the couple books and accounts for 50% of the total cost. Venues today seek to help the couple in their wedding planning by providing a physical service (in-person, email, phone). This is resource-draining and inefficient for the venue whilst time-consuming and stress inducing for the customer. We sell software to venues that enables them provide a online service to their customers as well as improve how they manage weddings internally. Key benefits to the venue include automation of 50,000 customer interactions and reducing wedding manger administration time by 9 weeks annually (17%). We already have 30% market penetration in Ireland and have begun expansion into UK & Spain.

Revenue Model Eventovate’s software is B2B2C. We charge the venue – they use part of the software internally and pass part of it on to their customers for free. The product suite is SAAS based and is a monthly recurring charge (€300 per month per venue). There is significant opportunity to generate additional revenue streams from the couples however the focus for this round of funding is to grow the installed base of venues (footprint). A typical customer (venue) has a positive ROI for Eventovate within 3mths. We have a churn rate of less than 5%.

Management Team The CEO spent 8 years as an international brand manager for Procter & Gamble – heading a female-products division with €170m in turnover and a team of 30. The CTO spent 10 years with Intel and led a global software development team. The key team requirement is experienced international SAAS sales managers.

Milestones - Product developed.

- Successfully raised seed funding.

- Customers in ROI, UK & Spain.

- Leads in Dubai, Turkey, US.

20

Target Markets Eventovate’s key focus is to grow its base of venues in Europe & US. This requires a combination of an inside sales team (focused on independent venue) and local-market business development mangers (focused on chains). The product is already available in multiple languages and we have sales resources in ROI, UK and Spain.

Funding Requirement

€4,000,000

21

Global Business Register Arclabs Research Center, Carriganore, Waterford www.globalbusinessregister.com

Company Overview GBR seeks to make the Internet a more trusted place where everyone can feel safe when communicating, transacting or conducting business online. We are committed to helping companies and individuals establish their verified identity online, proving you are who you say you are, thereby creating a trusted environment for all. We are constantly working on technologies that gather information from official registries and other web sources which enable the consumer to make a more informed decision about who to trust when they do business. With our portal to over 70 companies registers around the world, with direct access to official company information on over 55 million companies, we develop software to automate the identity verification process for financial KYC / AML and other compliance systems.

Market Opportunity The market driver for all our products is the increase in fraud. In 2010, fraud in the EU cost €360 billion and continues to grow. Governments want to reduce this and are mandating extra measures be implemented through increased regulation.

Company Information is a $10 billion market globally per annum. Due to increased regulation for Know Your Customer and Anti-Money Laundering solutions the market for official registry information is growing much faster than the rest of the market. We believe that reliance on third party providers for this information is already diminishing and that regulated organisations will place increased reliance on registry data from official sources.

Revenue Model Our revenue model is both transactional and license based. Registry data is currently transactional. Every document is sold individually.

We are presently negotiating a license model with the registries. Our other products are sold on an annual recurring license basis.

Management Team Ben Cronin C.E.O. - Ben 's background is in property development having run his own development firm. Prior to that Ben was a professional rugby player and played for Munster and Ireland. He studied Business in Waterford Institute of Technology.

Robert Leslie C.O.O. - Robert held senior management positions with Datacraft Japan as Director of I.T and Business Systems, PTS Limited as Director for Systems Integration Services and Dell Japan where he was part of the initial management team that launched Dell into the Japanese market. Robert has a degree in Electronic Engineering from DCU

Milestones 2007 Company Founded

2009 Contract signed with EBR and registry network launched

2010 Signed contract with GlobalSign

2011 Launched Trust Passport product

2011 €650,000 seed funding raised from GlobalSign, founders, others

22

2011 Expanded companies registry network to 70+ registers

2011 Shortlisted - Innovation of the Year - Irish Internet Association

2011 Shortlisted - Startup of the Year - Irish Internet Association

2012 Launched GBR SmartLogo product

2012 Selected as EMEA semi-finalist for Swift Innotribe

2012 Winner of Mobile Technology Project of the Year from Irish Technology Writers

Customers HSBC (UK), RBS (UK), Deutsche Bank (UK), UBS (UK), Deloitte (UK), KPMG (UK), Ernst & Young (UK), PWC (NI), Comodo (USA), GlobalSign (USA), various government organisations in multiple countries.

Target Markets Official Company Information - Financial Services, Legal & Accounting

Trust Passport - Internet Service Providers, SSL issuers

GBR Smart Logo - Certification Bodies, High Value Brand Owners

Funding Requirement €2,000,000

23

Lighthouse BCS 33-35 Wicklow St, Dublin 2 www.lighthousebcs.com

Company Overview Lighthouse BCS provides Supply Chain Finance and working capital management services to enterprise and public sector clients.

Lighthouse BCS addresses a need for companies to access additional sources of capital within their supply chains, and for banks to provide finance to businesses in a scalable, risk-effective way.

Over the last four years, the company has developed a unique solution addressing the end-to-end process for Supply Chain Finance, backed by state-of-the-art cloud-based technology. It has solved many difficult technical, operational and legal problems which had previously hindered the development of Supply Chain Finance. Lighthouse BCS offers a multi-funder, bank-independent solution which gives supply chain control back to the buyer, and offers best value for finance to their supplier base.

The Lighthouse service is now being used by hundreds of clients across Europe.

Market Opportunity Internationally, the availability of working capital has become a major issue for companies of all sizes. As a result, buyers of goods and services are tending to pay their suppliers later; however, suppliers are seeking to be paid earlier. The gap between buyer terms and supplier terms provides an opportunity for Supply Chain Finance. The Lighthouse SCF platform automatically connects trading partners with banks and fund managers who are prepared to finance approved invoices early in return for a small supplier discount. Risk assessment is based solely on the standing of the buyer, and this allows us to provide a scalable solution to large supply chains at very attractive rates.

Revenue Model Lighthouse BCS uses a multi-tiered revenue model. It provides services to organisations with large supplier bases free of charge, and generates revenues from supply chains as usage grows. The primary source of revenue for Lighthouse is as a portion of any supplier discounts given for early payment - whether as a Supply Chain Finance transaction, or as part of a buyer-led Early Payment Programme. Lighthouse also benefits from transaction fees to suppliers for processing and paying invoices, and fees for value-add services aimed at tax recovery, grant claims and other finance challenges.

Management Team The company was founded and is managed by Padraic Moran and Donal Sullivan.

Padraic spent twelve years as an IBM executive before creating a specialist VC fund for tech start-ups. He has 30 years experience of building businesses and managing large-scale operations in the Financial Services industry.

Donal has worked for many years with IBM and other companies in Financial Services technology. He implemented the first mobile, distributed and micro-payments systems for the Irish Post Office, as well as managing major integrated internet banking programmes for pan-European corporate banks.

24

Milestones 2008 Lighthouse BCS launched

2010 Initial product launched

2010 First reference client achieved

2011 First funding round closed

Oct 2011 Highlighted as a 'Company to Watch in Supply Chain Finance ' by analysts Aite Group

June 2012 Irish Revenue approval received for corporate VAT recovery solution

July 2012 successful completion of pan-European electronic invoicing pilot for Irish Government (PEPPOL)

August 2012 first government client secured

Customers Deloitte (IRL)

Celtic Media Group (IRL)

Arvato Digital Services (GER)

Galway County Council (IRL)

Target Markets The Lighthouse service is applicable in any industry vertical where businesses actively trade in goods and services. A typical target client has annual revenues in excess of €500m, and procurement spend on goods and services of over €100m.

Funding Requirement €2,000,000

25

OmniMotion 49 Hanover Riverside, Sir John Rogerson’s Quay, Dublin 2 www.omnimotion.com

Company Overview OmniMotion has developed a proprietary and instantly scalable technology that integrates accurate, versatile Motion Control / Gesture Recognition into any content, for any device with a camera - no peripherals required!

Motion Control is emerging as one of the fastest growing and key strategic categories in technology, with OmniMotion’s offering enjoying significant advantages over all of its competitors due to its massively broader deployment potential, lower cost and versatility of performance.

This technology, presented under the 'MotionSDK' brand, is available within an easy-to-use Software Developer Kit ('SDK') including an integrated 'Plug-In' that complements popular authoring/content development tools such as the Unity games engine.

OmniMotion has already commenced the recruitment of partners, supported by reference apps, which will culminate in an Ecosystem of Developers that can quickly deliver more titles and more users, in turn, setting the standard in Motion Control.

Market Opportunity It is estimated that in 2012, licensing revenue from the Motion market will be €659.5m, rising to €3bn+ within 4 years.

Competitive Motion solutions are predominantly based on dedicated 3D hardware requiring $100+ p.u. 3D cameras, slowing the rate of adoption.

OmniMotion can 'set the standard' by immediately supporting 3rd parties (primarily Funded Independent's and Hobbiests) in releasing games and applications for end-user's existing devices (primarily Tablet and mobile), distributed through standard channels such as the App Store.

Building on current clients that include the Olympic Movement, and NewsCorp, OmniMotion will also offer Enterprise Services to brand leaders.

Revenue Model The business model has been designed to maximize revenues by minimizing barriers to usage, including free distribution of the basic SDK, followed by a 'per user' royalty charge of ¢10 per download. With a choice of payment options and a pricing strategy roughly equalling typical financial transaction charges, developers in turn will be incentivized to quickly embrace the technology as a key discriminator for any application or game, with such an additional feature also capable of commanding a premium price for the title.

Management Team - Niall Austin – Founder and CEO. 25-year veteran in Marketing Services industry. Specific responsibility for Sales and Marketing.

26

- Paul Cooke - COO. Former MD at The Star Newspaper. Responsibility for Operations and General Management.

- Jason Brennan – Chief Scientist. An engineer with 25 years experience in gaming technology. Responsible for Innovation and Content.

- Damian Power - CTO. A Computer Scientist with over 20 years experience in Back-End Solutions and Integration.

Milestones 2006 - Initial development of concept, with focus on Sports and Health.

2009 - Initial launch of trial online solutions.

2011 - Company raised €500,000 from DBiC and Enterprise Ireland.

2012 - MotionSDK beta attracts 150 initial testers.

- Launch of MotionSDK and reference apps (October 2012).

- Licensing of technology to several Enterprise Clients.

Customers   Customers include the Olympic movement (UK, Italy and Ireland), Endemol (International), Sky (UK) and NewsCorp (USA).

Local licensing customers include Horizon and UniSlim.

Target Markets OmniMotion is seeking mass deployment of it's SDK among Independent, funded Independent and Hobbiest Developers, initially focusing on Unity Developers.

OmniMotion is also seeking collaborations with companies within the Healthcare, Media and Display Signage categories for specific applications.

Funding Requirement €1,500,000

27

Phorest 100 Capel St, Dublin 1 www.phorest.com

Company Overview Phorest provide an online booking and CRM platform for the hair and beauty industry. Salons use it to manage appointments, CRM and client records. Consumers use to find and book appointments online in those salons or spas.

The company is growing rapidly and will generate revenues of €2.2m this year.

Market Opportunity 5 billion people visit 4 million salons and spas on a regular basis worldwide. The vast majority of these salons do not have a dedicated receptionist so consumers struggle to get through to someone when they want to book an appointment.

Phorest currently serves 850 salons, 500,000 consumers in the UK and Ireland and is looking to launch into the US market which has 500,000 salons and 180m potential consumers.

Phorest want to become the OPEN TABLE of the Hair and Beauty Industry.

Revenue Model Phorest earns an upfront fee per salon and then an average of €150 per month per salon. Phorest earns €1 per online booking.

Management Team Ronan Perceval (CEO), Co Founder Demonware 2003, sold 2007 €15m to Activision. 9 Years in software and hair and beauty.

Sue Maguire (Sales Director) Ex Dermalogica and Jessica Nails. 25 Year veteran of Beauty Industry in UK and Ireland.

Eamon Walshe (CTO) Ex IONA and CTO STORM HQ, One of the best known Agile Coaches in UK and Ireland.

John Kennedy (CFO) 20 Years Qualified. Ex Managing Partner of 25 Man Accountancy Practice.

Milestones 2008 - Salon CRM Software Locally installed

2009 - Online Booking Prototype

2011 - Seed Funding €1.2m

Apr 2012 - Web Based Salon Management Platform Released

Nov 2012 - 850 Salons, Annual Sales €2.2m

28

Customers 850 Salons and Spas throughout the UK and Ireland including some well known names such as:

Spa NK

Clarins

Environ

The Pottingshed (Medium Sized Salon of the Year 2012)

Easthorpe Hall

Target Markets Currently targeting Salon and Spas in the UK and Ireland. Looking to use funding to develop the online booking platform and launch into the US market.

Funding Requirement €3,000,000

29

ServiceFrame Value Management NovaUCD, University College Dublin, Belfield, Dublin4 www.serviceframe.com

Company Overview ServiceFrame is creating the worlds's smartest outsourcing relationships by using technology to deliver consistent excellence in outsourcing governance. We develop and sell software to automate the processes underlying relationship governance in outsourcing. 50% of outsourcing engagements fail and with that failure there is always a breakdown in the relationship. ServiceFrame protects the enterprise from the threat and consequences of that failure.

Service Providers buy ServiceFrame to insure the relationship with their customer.

Service Consumers buy ServiceFrame to insure themselves against supplier failiure.

Market Opportunity Market - Outsourced network operations in the telecoms sector, c€60b. Total addressable market is c€3b. The serviceable/achievable market for ServiceFrame is c€100m p.a. ServiceFrame is targeting the service providers in this segment - Ericsson, Huawei and others. Enormous pressure and change in the market, such as new devices, data demands and the high cost of failure means the risks to the relationship are very high. Service Providers are buying ServiceFrame to protect themselves against this risk.

There is a very substantial additional opportunity in other segments - non-Telecoms Network Operations, Finance Operations, IT Services in Telecoms - SOM €100's m.

Revenue Model Customers buy an implementation project and recurring annual license fees. Current deals averaging €150k annually in license fees, with an implementation project of €120k on average. Value to ServiceFrame €870k; with recurring income over 5 years of €150k and upsell opportunity.

Management Team Diarmuid Barry (CEO) – strategic focus and execution. Former group head outsourced engineering services at Microsoft

Daniel Berman (CTO) - Product design and build. Outsourcing Delivery Manager at Accenture

Milestones 2009 Prototype built

2010 First customers signed up

Q1 2011 Seed round investment of €950k - Kernel Capital, Enterprise Ireland, Private Investors

Q3 2011 refocused proposition and targeted Telecoms network operations as the market segment.

Q2 2012 Price point and Telecoms managed network operations market proven.

30

Customers Ericsson - US, US, Africa, Telecoms Managed Services

Unisys - US, Europe IT services, Finance Operations

Serco\Steria - UK, BPO, FInance Operations

Target Markets 2012\2013 - Telecoms Network Operations managed services

2013\2014 - Add Enterprise Managed Network Services

2014\2015 - Add Telecoms IT services, potentially Finance Operations - BPO and Shared services in future.

Funding Requirement €3,000,000

31

UniVirtua Ireland Ltd 31 St Anne’s Square, Portmarnock, Co Dublin www.univirtua.com

Company Overview In 2006 UniVirtua’s research identified two key problems with the fast growing mobile sector, namely that of on-device security and application agility. Out of this was born the Majic Mobile Platform, built on unique and patented technology that addresses these and many other challenges. Today the issue of security is paramount and Majic is the only product available that provides the means develop mobile apps that leave NO data on the device after use. Majic’s versatility also allows rapid application development, product scalability and the ability to ‘shape-shift’ the application to adapt to varying network conditions.

Market Opportunity By the end of 2013, global demand will exceed 1.5 billion smartphones and 150 million tablets. Conventional apps built for these devices pose a serious data security threat for business and consumer users by allowing sensitive data to loiter on the device after use. Furthermore, corporate policy now reluctantly accepts BYOD (bring your own device) for employees yet every BYOD is a serious security risk, exposing to loss sensitive corporate or client information. UniVirtua addresses these and other issues with its patented Majic platform, enabling programmers to build and deploy apps for smartphones, tablets and low resource devices that boast unique security and functionality.

Revenue Model The revenue model enables an aggressive growth that does not require rapid organisational development and related investments, but is rather realised through a high revenue annuity ratio. The pricing model we have developed consists of:

■ Pilot Fee - €50,000

■ Initial licence fee - €40,000

■ Server maintenance fee - 20% of the server installation fee per annum

Management Team Joseph Poole - CEO & Co Founder

Rohan Beckles - VP Technology & Co Founder

Professor Damien McDonnell OBE - Chairman

John Smith - Director of Sales

Derek Clements - Director of Marketing

Martin Baker – Director of Communications

Milestones ■ UK Patent granted (Patent No: GB2443846)

■ US Patent awaiting grant Oct 12

■ EU PCT at examination stage

■ Trade Mark secured

32

■ Documented independent validation by University College Cork

■ Majic validated /approved by leading Forensic Testing Company

■ Reseller Agreement with Pegasus Global for Defense in USA

■ Co-developing UK Mobile Health solution with 2e2

■ Co-developing Mobile Share Trading platform with Sharewatch

■ Prototyping Secure Payments System for MasterCard

■ Classified as a HPSU by Enterprise Ireland

■ Co-bidding with UCC for Science Foundation Ireland funding to develop mHealth Remote Monitoring System

Customers Pegasus Global signed Contract

Awaiting signed contract with 2e2

Awaiting signed contract with Sharewatch

Target Markets Financial Services, mHealth, Defence, Blue Light Services and Gaming.

Funding Requirement

€3,000,000

33

Crescent Diagnostics NovaUCD, University College Dublin, Belfield, Dublin 4 www.crescentdx.com

Company Overview Crescent is developing BQT, a 5-minute non-invasive predictive test for bone quality and hip fracture risk.

BQT uses nail keratin as a surrogate biomarker for bone collagen.

The Raman Spectrum of nail measures the structural protein, keratin. Adverse changes in keratin are reflected in bone collagen.

Market Opportunity The market for osteoporosis diagnostic tools is large, growing and worth up to €1.2bn.

• 100 million women aged from 50-69 in EU & US. • 20 million DXA scans completed per year in EU & US. • Aging population demographics to increase demand.

Crescent has an experienced management team with Plc, VC start-up and exit experience.

Revenue Model Revenue will be derived from the usage of Crescent’s proprietary software on a “pay per click” basis.

Management Team Brendan K. Farrell MSc. - Chief Executive Officer

Brendan has over 30 year’s experience in the Diagnostics industry and became CEO of HiberGene Diagnostics in 2009, moving to Executive Chairman in 2012. From 1994 to 2008 Brendan was the President/CEO of Trinity Biotech plc., a NASDAQ listed diagnostics company. He was instrumental in growing the company from revenues of $3 million to $140 million and from loss making to sustained strong profitability. Mr. Farrell has extensive international experience in marketing and sales, licensing and acquisitions, fundraising, investor relations and general management.

Renwick Beattie, PhD. - Senior Scientific Officer

Renwick is a highly experienced analytical chemist with over a decade of experience working at the interface of spectroscopy and biomedicine. His work at Queen’s University of Belfast focused on the development and application of Raman spectroscopic methods in the analysis of biomedical issues. He has published the results of his extensive research in 24 peer reviewed internationally recognised scientific journals and at numerous international conferences.

Marie Rooney MSc. - Project Director

Marie has 20 years’ general management experience in the healthcare industry with particular experience in. Ms. Rooney was Operations Manager with Trinity Biotech Plc. Previously, Marie was an R&D scientist with Cambridge Diagnostics Ltd., a wholly owned subsidiary of Inverness Medical Innovations inc. Marie is a graduate of the University of Limerick and holds a Masters degree in Project Management.

34

Orlaith Brennan PhD. – Clinical Project Manager

Orlaith has extensive expertise in bone quality assessment, mechanical characterisation of biological tissues and bone cell biology, having carried out a PhD on "Bone Quality and its Relationship with Bone Fragility and Osteoporosis" at Royal College of Surgeons in Ireland and worked at research laboratories in Australia, the UK and Ireland. Orlaith is a graduate in Experimental Physics from Trinity College Dublin, from where she also holds an MSc in Biomedical Engineering

Milestones Crescent Diagnostics was established in 2004 to develop and commercialise this technology. Initial seed funding for this research work was provided by life science investor Seroba BioVentures, private investors and Enterprise Ireland. Crescent’s early trials served to establish the initial clinical signal and provided experience in the development of algorithms for use in the pivotal studies.

Crescent established clinical validity for BQT through a pilot study conducting within the Nurses’ Health Cohort Study (Harvard University). This study was equivalent to a 2,000 women study conducted over a 20-year follow-up period. Following this breakthrough study, Crescent closed a €1.5m Series A funding round in April 2011, financed by Seroba, Kernel and Enterprise Equity

Customers Pre- Revenue

Target Markets Hospital and reference laboratories, women’s health clinics.

Funding Requirement Crescent is seeking to raise €4,500,000 to achieve the following:

• Successful Clinical Validation. • Proprietary instrument & consumable. • CE Mark & FDA clearance.

35

Inflection Biosciences Suite 15, Anglesea House, Carysfort Avenue, Blackrock, Co. Dublin

Company Overview Inflection Biosciences in-licenses and develops pre-clinical stage programs from academic institutes and drug companies globally, focusing on small molecule, targeted cancer treatments. Development will leverage in house expertise along with cost effect outsourcing, where appropriate, to progress a small number of programs from preclinical to clinical setting (Phase I/II). Revenue will be generated via onward partnering of its de-risked pipeline to larger oncology focused pharma companies.

Market Opportunity Today cancer is second leading cause of death after heart disease globally. While global sales of oncology treatments generate €80bn annually, significant unmet medical need remains and costs to the national economies are staggering. With increasing pressure on national health budgets, more expensive cancer treatments face great reimbursement challenges. Inflection Biosciences’ focus on small molecule and targeted cancer treatments will be better aligned with this need for affordable pricing.

With larger pharma reducing their own in house discovery capabilities in favour of buying in innovation there is a market for smaller, cost effective and focused companies like Inflection Biosciences to become a reliable source of de-risked pipeline opportunities for larger pharma.

Management Team Darren Cunningham (Founder and CEO) - 12 years industry experience, previously with Amarin Corporation plc, Elan Corporation plc, PricewaterhouseCoopers. Responsibilities for business development, fundraising, investor relations and intellectual property management. B Comm, M Acc, FCA.

Dr. Michael O’Neill (Founder and Director R&D) - 20 years industry experience, previously with Eli Lilly, Merck, Almirall. Responsible for progressing drug discoveries through to early clinical development. BA Psychology, PhD.

Advisory Panel – an international advisory panel has been assembled comprising industry leading expertise in oncology drug development, regulatory and clinical. Associated with discovery and development of a number of the approved and successful cancer treatments including Gleevec® and Hycamtin®.

Milestones International Advisory panel established

Target product profile created

Review of >150 opportunities from leading global institutes

Network of preclinical and clinical research providers

Angel round closed

36

Target Markets Larger oncology focused pharmaceutical companies

Funding Requirement Inflection Biosciences is seeking to raise €8,000,000 over the next three years to achieve the following:

Fund two targeted, small molecule cancer programs through to IND/CTA filing

Complete first in human trial on lead program

37

Metabolomic Diagnostics Suite 2.28, Western Gateway Building, Western Road, Cork www.metabolomicdiagnostics.com

Company Overview Metabolomic Diagnostics was setup in 2011 to exploit the commercial potential of biomarkers that detect and predict major complications in pregnancy. The company has licensed breakthrough technology from UCC that - through a simple blood test, analysed and classified in a clinical laboratory - can accurately predict pre-eclampsia after only 15 weeks gestation with extremely high accuracy. Our test Prepsia, available to the market in 2013, has global potential and can form part of pregnancy screening programs worldwide.

Market Opportunity Prepsia has the potential to halve the mortality rates of mothers and infants and, as a result of identifying at-risk pregnancies, can reduce the occurrence of bad outcomes by 75%. The resulting savings in healthcare cost and insurance claims in the US alone run to many billions of dollars each year. The global market is over 130 million pregnancies per year and Prepsia can form part of pregnancy screening programs worldwide generating significant annual revenues. The company intends to deploy these tests in the market in 2013 by licensing their promotion and delivery to major clinical laboratories and life science companies. We are at an advanced stage in these discussions.

Revenue Model Our revenue model is to charge a fee per test to licensed clinical laboratories. Current medical practice is to monitor ALL women during pregnancy in an effort to detect early signs of pre-eclampsia.

Management Team Charles Garvey (CEO) - Former CEO of Horizon Technology Group Plc. Built major pan European IT services group, 720 staff in 13 companies.

Paul Hands - Founder and former CEO of Qumas, Global leader in “Enterprise Compliance Management.

Diarmuid Cahalane - Former CEO of life sciences Quality and Compliance consulting firm. Worked with US & European regulators on behalf of global life science clients.

Prof. Louise Kenny - Professor of Obstetrics at UCC. Clinician and Scientist. More than 100 peer reviewed papers. Editor of world’s leading textbook in obstetrics. Key opinion leader in obstetrics.

Milestones 2012. Signed global license for technology from UCC

2012. Strengthened global patent license

2012. Secured 6m FP7 grant to conduct full hospital study

2012. Complete investment round

2012. Sign agreement with global clinical laboratory partners

2012. Sign agreement with Life Science partners

2013. First license revenues

38

2013. Begin hospital study and build valuable biobank

2013. CE Mark in EU and LDT license for US market approval

2013. Further test validation and licensing for new biomarker discovery into pregnancy complications.

Customers Key initial markets are the US and Europe

First customers will be global clinical reference laboratories offering Prepsia to the marketplace.

Target Markets Our target market is all pregnancies worldwide beginning with established screening programs in Western economies (region1).

Region 1. 11m EU, US, Canada, Australia, NZ and Japan

Region 1. 63m China, India, S. America

Region 2. 58m Asia, Africa, Specific

Funding Requirement

€3,000,000

39

Radisens Diagnostics The Rubicon Centre, Rossa Avenue, Bishopstown, Cork, Ireland www.radisens.com

Company Overview Radisens is developing a portable blood testing device to diagnose and monitor long-term chronic diseases such as thyroid disorders, diabetes, kidney function and heart disease. With a single drop of blood, results are available within minutes at lab-grade performance. This disruptive platform has already led to Radisens signing strategic development contracts with three of the top six diagnostics multinationals. Our integrated approach drives significant cost reductions for managed care and healthcare insurers, introduces new revenue streams for physicians, closes the linkage between diagnostics and therapeutics, and significantly improves patient care. Radisens has 10 patents pending/granted, in addition to various commercial licenses to 3rd party IP.

Market Opportunity There is worldwide chronic disease epidemic across obesity, diabetes, heart and kidney disease. Studies show that regular blood monitoring reduces chronic disease risk factors, resulting in better long-term patient care and significantly reduced healthcare costs. Yet this market has no point-of-care solution to address the need for integrated sample-to-answer testing, thus limiting the growth of the decentralised testing segment. Radisens delivers on this unmet need, starting with a reimbursable thyroid test, before extending the test menu to the other main chronic diseases ($3.2bn niche for 1st four tests), and the world’s first cell counting test at point of care ($2.5bn niche).

Revenue Model Radisens is an OEM supplier of white-labelled diagnostic device and consumable blood tests to diagnostic multinationals. These customers brand and sell them through their existing distribution channels. Manufacturing of both the device and consumables is out-sourced under Radisens control. Radisens has early development contracts with three of the top six diagnostic multinationals, attracted by our unique ability to integrate the three primary blood test categories - high-sensitivity immunoassay, chemistries and haematology tests - onto single test panels.

Management Team Jerry O’Brien (CEO): 5 years (medical) and 13 years (consumer electronics) industry experience, with senior commercial and product development roles in start-up and high growth companies (Parthus, Frontier Silicon) focused on Far East, US and EU markets. Extensive business development, marketing, product launch & international sales experience.

Dr. Ian Hayes (Business Development).17 years commercial, business development experience in diagnostics and drug discovery industry with partnering, negotiation and licensing of multi-million dollar contracts with Opsona, Alimentary Health, Crescent Diagnostics, and Eirx Therapeutics

Dr. Eoin O’Nuallain (Chief Scientist). 25 years point-of-care diagnostic experience at Trinity Biotech (leading the HIV diagnostic development) and Biosensia, from early assay design through clinical trials and regulatory approval. UCD PhD (’89: Biochemistry)

Dr. Damian Curtin, (Product Manager) 13 years microfluidics experience; previously held senior R&D management roles at Stokes Bio, with numerous patents and delivery of commercial contracts to major clients, before its sale to Life Technologies. UL PhD (’06: microfluidics)

Lee Barry (Engineering). 18 years semiconductor industry experience holding senior engineering, operations and management roles at Parthus, Ceva, after early bioelectronics research career. UCC M.Eng.Sc. (’93: Microelectronics).

40

Milestones 2008 Market Research: market need, use case & business model validated

03-09 Incorporation: with promoters funding;

3Q-09 Unique disruptive technology identified. First patent filed;

3Q-10 Funding: €500k grant for detection platform; Becton Dickinson as partner

2Q-11 Funding: €1.3M seed funds to develop 1st blood test & consumable platform.

3Q-11 Contract: NHS (UK) contract to develop kidney test;

4Q-11 Contract: €1M with European Space Agency (ESA) to develop thyroid test;

2Q-12 Contract: Beckman Coulter development partnership for detection platform

3Q-12 1st integrated blood test prototypes: thyroid & kidney tests; 10 patents;

3Q-12 Contract: Partnership with leading Diagnostics OEM on diabetes

1Q-13 Commercial Alpha device running integrated thyroid and kidney tests;

1Q-13 Contract: €1M follow-on ESA contract for thyroid test development;

1Q-14 Clinical Trials commence with thyroid test

3Q-14 Launch: CE regulatory approval and German market launch with thyroid test

2Q-15 Launch: 510(k) approval and U.S. market launch

Customers   Contracts: Beckman Coulter, a Top3 Diagnostics Multinational, European Space Agency, NHS

Trials completed: Becton Dickinson,

Project scoping: Roche Diagnostics,

Early diligence: Life Technologies, Merck Millipore, Hemocue, Quidel, Abbott Diagnostics, Fujirebio, Sekisui, Randox

Target Markets Initial launch with thyroid test in Germany after CE approval (2H-14), before expanding into Scandinavia and UK. US launch after FDA 510(k) regulatory approval in 1H-15. Roadmap to extend test menu to offer diabetes, kidney function, heart disease and cell counting panels.

Funding Requirement

Radisens is seeking to raise €5,000,000 to deliver:

• Proprietary instrument & consumable (thyroid test).

• Successful Clinical Validation.

• CE & FDA regulatory approval.

41

Sigmoid Pharma Ltd. Invent Centre, DCU, Dublin 9 www.sigmoidpharma.com

Company Overview Sigmoid Pharma Limited is an innovative drug-delivery-enabled specialty pharma company. Sigmoid uses proprietary SmPill® technology to facilitate reduced-risk, innovative, patentable product development, largely for gastrointestinal diseases. Sigmoid has advanced its lead product, CyCol®, through Phase 2 for ulcerative colitis and will enter pivotal registration studies in early 2013. Sigmoid has a pipeline of Phase I stage products, including one for Crohn's disease and a FDA Orphan Drug designated Graft-versus-Host Disease product as well as a number of pre-clinical prototypes. SmPill® technology has demonstrated potential in the oral delivery of vaccines and peptides.

Market Opportunity Gastrointestinal disorders affect more than 250M in the 7 major markets; the prescription segment is worth more than $25B. Ulcerative Colitis (UC) is growing, estimated to exceed $7B in 2011. UC affects 750,000 patients in the US alone, and global sales are >$1.5B. CyCol® is aimed at moderate to severe patients, where existing therapies are sub-optimal. As an oral, safe and effective therapy, CyCol® will have a competitive advantage. The vaccine market is the fastest growing segment in the industry. The global drug delivery market exceeds $130B, and bioavailability and poor water solubility are consistently listed as the greatest needs - both of which are addressed by SmPill®   

Revenue Model Sigmoid expects to generate revenues from three sources

- Products: Fees, milestones and royalties on sales through outlicensing global or regional rights to product development pipelie

- Technology: Fees for applying SmPill® to other pharma companies' formulation challenges. Milestones and royalties on the license to use SmPill® in commercial product

- Manufacturing: Sigmoid will retain manufacturing rights to the core bead manufacture and supply to partners at a margin above COGS

Management Team Dr. Ivan Coulter, CEO and founder. Inventor of SmPill® and CyCol®. Previously at NTera. PhD from UCD, Post-Doc Fellowship at Institut Curie, Paris and Fulbright Scholar at Cornell, MBA

Dr. David Roblin (Chief Medical Officer) joined from Pfizer; was head of Research in Europe. Held senior roles at Bayer. Fellow of the Royal College of Physicians

Rosemarie Tully (Chief Business Officer) Extensive pharma business development and strategy experience at Elan and McKinsey. Pharmacist with MBA from INSEAD

Milestones Met FDA and 3 European regulatory organisations to agree CyCol® clinical development plan in October 2012

Completed phase 2 trial in over 100 ulcerative colitis patients in May 2012

Raised €3 million private funding January 2012

42

Completed phase 1 trial in healthy volunteers September 2011

Initiated Phase 2 trial in UK and Ireland May 2009

Established IMB approved clinical trial manufacturing facility in 2008

Filed 14 patent families, a number of which have been granted by the EPO

Awarded EU FP7 grant to advance oral vaccine development

Consortium member in a number of national and international research networks, including vaccines and nanotechnology

Customers   - Leader of EU FP7 €1.2 million consortium to develop oral helicobacter pylori vaccine

- Irish Drug Delivery Network consortium member

- EU FP7 ADITEC consortium member

Target Markets Global ulcerative colitis market

Global Crohn's disease market

Global Graft versus Host Disease market

Travellers diarrhoea vaccine market

Drug Delivery technology market

Oral vaccine delivery market

Oral peptide delivery market

Non-pharma applications, incl. medical or functional foods

Funding Requirement

€15,000,000

43

Solvotrin Therapeutics Hoffmann Park, Inchera, Little Island, Cork www.solvotrin.com

Company Overview Solvotrin Therapeutics is a drug development company with a streamlined route to market for lead compound ST0702 in a rare cholesterol disease. Post launch research will enable expansion within the $30 billion large cholesterol market. The Company is in an exceptional position to demonstrate the value of the compound in humans at the early stage of Phase I, which will allow an early exit for investors within two to three years.

Market Opportunity Type III Hyperlipoproteinaemia is a rare lipid disease in which current response rates to treatment are poor and patients have very high lipid levels. This can result in serious cardiovascular complications and premature death.

Patients can present as early as in their late teens which means that tolerability issues with current treatments are not acceptable in the long term. Niacin (Niaspan®) is currently used despite poor tolerability, especially flushing. Five in six patients stop taking Niaspan® within 12 months, but it still has sales of $1 billion/year. A therapy that could provide increased effectiveness with a better tolerability profile would be welcomed by patients, clinicians and regulators.

Management Team Pat O’Flynn, CEO - An Ernst & Young Entrepreneur of the Year finalist (2008), with a proven track record in developing and building international business and joint-venture partnerships.

Dr. Mark Ledwidge, VP Development and Strategy - PhD in pharmaceutics and expertise in pharmaceutical marketing and translational drug research

Dr. John Gilmer, VP Research and Development - Expert in prodrug technology and an pharmaceutical IP

Dr. David Howat, Consultant Project Director - PhD in Biochemistry and 25 years experience in preclinical drug development

Dr. Eugenio A. Cefali, Consultant Project Director/ Industry Advisor - Former VP of Lead Optimisation at Kos Pharmaceuticals (Abbot) and played a major role in the development of Niaspan®

Dr. Peter Milner, Medical and Industry Advisor - Co-founder of a number of successful biotechnology companies.

Prof. Damian O’Connell, Medical and Industry Advisor - Former VP of Research at Pfizer and current Senior VP of Translational Drug Development at Bayer.

Prof. Moti Kashyap, Medical Advisor - Director Atherosclerosis Research Centre, Veterans Affairs Healthcare System, California, USA

Prof. Frank Visseren, Medical Advisor - Professor of Vascular Medicine at the University Medical Centre, Utrecht, The Netherlands. A clinical lipid specialist for patients with severe lipid diseases.

44

Milestones

Completed preclinical “proof of concept” in non-human primates, first patent grants and regulatory and market access route defined.

Target Markets Healthcare Sector, Pharmaceutical Firms

Funding Requirement €5,500,000

45

Surgacoll Rubicon Centre, Bishopstown, Cork www.surgacoll.com

Company Overview SurgaColl™ Technologies Ltd. has developed a range of exciting regenerative technologies based on almost a decade of world class tissue engineering research carried out in the Royal College of Surgeons in Ireland (RCSI). The company's innovative product portfolio is based on a suite of common-platform technologies that offer regenerative solutions in the field of bone (HydroxyColl™) and cartilage/osteochondral (ChondroColl™) tissue regeneration.

SurgaColl™ Technologies' products support the body's own natural healing processes, using highly biocompatible, bioactive, and naturally-derived materials to promote faster tissue regeneration without sacrificing quality of healed tissue. SurgaColl™'s technologies are a safe and natural solution to the active patient's demand for rapid return to a healthy and active lifestyle.

Market Opportunity The global bone graft substitute market currently exceeds $4.3bn (2009) and is forecast to reach $9.6bn in 2016. Surgacoll's initial product Hydroxycoll is targeted at this market. SurgaColl believes it has several sales and out-licensing opportunities for various applications of its products.

In addition, the potential market for cartilage repair and osteoarthritis affect at least 40 million Americans alone. None of current cartiable repair therapies currently available adequately addresses this unmet clinical need. SurgaColl's second product ChondroColl addresses this global market which is estimated of upwards of $3billon annually

Revenue Model SurgaColl will sell their products directly to hospitals/surgeons as well as through resellers and under private label.

Management Team Dan Philpott, Founder/Chief Executive Officer - has previously held senior positions with Digital Equipment Corporation, Intel Ireland and Johnson & Johnson. Most recently co-founded a medical device company, EnBIO, and as CEO and director grew the company with a highly successful fund raising and customer engagement campaign.

Pat Forristal, Founder/Non Executive Director and Chairman - has held a number of senior leadership positions in the Pharmaceutical, Medical Devices and Engineering industries, both in Ireland and internationally

Dr John Gleeson – CTO - one of the inventors of the SurgaColl technologies. He is currently the Project & Business Development Manager for the Tissue Engineering Research Group in RCSI.

Brendan McGrath - Global Marketing & Sales Director - over 30 years experience in engineering, R&D and marketing with orthopaedics industry leaders, including Howmedica, Stryker and Smith & Nephew

Frank Coombes – CFO - over 15 years experience in corporate finance

46

Milestones Oct 2010 - Company founded

Feb 2011 - Heads of Agreement with RCSI to license technologies for commercialisation

May 2012 - Closed seed capital funding of €2.2m

June 2013 - CE Mark for HydroxyColl™ allowing first product to go to market

Feb 2013 - Phase 1 ChondroColl pre-clinical trial complete

Aug 2014 - ChondroColl™ CE mark approval

Customers Initial product Hydroxycoll will be ready for market in Q2 2013 for which several Tier 1, 2 & 3 OEMs have expressed interest in, for private labelling purposes. ChondroColl™ has widespread interest.

Target Markets SurgaColl initially has two target markets:

(a) The bone graft market with the product HydroxyColl and SurgaColl expect to be in this market by Q2 2013

(b) The cartilage repair and osteoarthritis market with the product ChondroColl and SurgaColl expect to be in this market by Q2 2015

Funding Requirement €5,000,000

47

TriMod Therapeutics The Tower, Trinity TEC, Pearse Street, Dublin 2 www.trimodtx.com

Company Overview Using groundbreaking patent protected science, TriMod is developing a novel therapy that instructs a patient’s immune system to target and destroy tumours. Success has been demonstrated in animal models of melanoma, colon and lung cancers that are large market opportunities. The founders have extensive experience and demonstrated success in academia (TCD, UC London, NUIG, UCSF)and industry (Genentech, Opsona) and have attracted an experienced Board of Directors to direct this exciting science through the clinic and onto the market.

Market Opportunity Cancers actively suppress the immune response to enhance its survival. TriMod’s therapeutic approach removes this suppression allowing the immune system to attack and kill the tumour, including metastatic sites far from the primary tumour.

Product Using a combination of two potent and selective small molecule drugs, TriMod manipulates key cell signalling pathways to expose tumours for destruction by the immune system. Pre-clinical studies will be rapidly followed by human proof of concept studies using the Irish clinical trials network. TriMod has identified a diagnostic marker that will enable early detection of therapeutic success.

Revenue Model Cancer therapeutics is a large and growing market ($47bn globally in 2009) due to aging populations with many existing therapies generating over $1bn in annual revenues. Advancing science reveals new approaches that have significant advantages over existing therapies. TriMod intends to exploit this. Following Series A financing and human clinical trial success, TriMod will partner with a Pharmaceutical or Biotech company to fund and develop the technology further. Such non-dilutive funding and a likely future acquisition by the partner company will provide a significant return for investors.

Management Team The TriMod team is uniquely positioned to develop this cancer vaccine technology. Inventor, Prof Kingston Mills is a globally recognised expert in this field. TriMod’s co-founder, Dr. Jeremy Skillington, has 10 years experience in the Biotech industry (Genentech, Opsona, TriMod) and has successfully raised the Seed Capital financing, driven the TriMod strategy and established the existing key collaborations. TriMod’s highly experienced cancer-focused Board complements the co-founders, promising assured guidance for future development efforts.

Milestones • Multiple Pharma / Biotech collaborations signed • In vitro / in vivo Proof of Concept demonstrated

Target Markets Healthcare sector, Pharmaceutical companies

Funding Requirement €7,500,000 (Series A – 2013)

48